Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZS802
- Development stage
- Phase 2
- Lead developer
- Real & Best Biotech
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
ZS802 is an investigational adeno-associated virus (AAV)-based gene therapy developed for the treatment of Hemophilia A. It delivers an optimized and modified human coagulation factor VIII (F8) gene sequence using a proprietary, liver-specific promoter designed to enhance expression and efficacy. The therapy aims to provide long-term correction of factor VIII deficiency by enabling patients' own liver cells to produce functional factor VIII protein, thereby reducing or eliminating the need for exogenous factor VIII infusions. Clinical studies are ongoing in China to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy in patients with severe Hemophilia A[1][2][4].
- Other names
- ZS802 injectionZS-802 injectionZS 802 injection
02
Targets
F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on ZS802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZS802.